ondansetron has been researched along with Adverse Drug Event in 20 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary aim of this study was to compare the effectiveness of olanzapine, palonosetron and ondansetron infusion (standard of care) for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients undergoing hematopoietic stem cell transplantation (HSCT)." | 9.24 | A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. ( Barras, M; Butler, JP; Curley, C; Kennedy, GA; Nakagaki, M, 2017) |
| "Palonosetron has shown efficacy in the prevention of chemotherapy-induced nausea and vomiting in adults undergoing moderately or highly emetogenic chemotherapy." | 9.22 | Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. ( Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE, 2016) |
| "The neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed in adolescents." | 9.14 | Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. ( Carides, AD; Chawla, S; Chua, V; Devandry, S; Evans, JK; Gore, L; Hemenway, M; Oxenius, B; Petrilli, A; Schissel, D; Taylor, A; Valentine, J, 2009) |
| "At several out-of-hours services primary care, a single dose of ondansetron was compared with standard care (oral rehydration solution (ORS)) in young children with gastroenteritis and persistent vomiting." | 8.12 | [No place for ondansetron in young children with gastroenteritis and persistent vomiting]. ( Wichers, IM, 2022) |
| "The primary aim of this study was to compare the effectiveness of olanzapine, palonosetron and ondansetron infusion (standard of care) for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients undergoing hematopoietic stem cell transplantation (HSCT)." | 5.24 | A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. ( Barras, M; Butler, JP; Curley, C; Kennedy, GA; Nakagaki, M, 2017) |
| "Palonosetron has shown efficacy in the prevention of chemotherapy-induced nausea and vomiting in adults undergoing moderately or highly emetogenic chemotherapy." | 5.22 | Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. ( Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE, 2016) |
| "The neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed in adolescents." | 5.14 | Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. ( Carides, AD; Chawla, S; Chua, V; Devandry, S; Evans, JK; Gore, L; Hemenway, M; Oxenius, B; Petrilli, A; Schissel, D; Taylor, A; Valentine, J, 2009) |
| "Ondansetron has shown good efficacy in the prevention of acute nausea and vomiting in children receiving moderately or highly emetogenic chemotherapy and/or irradiation, particularly when combined with dexamethasone." | 4.81 | Ondansetron: a review of its use as an antiemetic in children. ( Bhana, N; Culy, CR; Plosker, GL, 2001) |
| "At several out-of-hours services primary care, a single dose of ondansetron was compared with standard care (oral rehydration solution (ORS)) in young children with gastroenteritis and persistent vomiting." | 4.12 | [No place for ondansetron in young children with gastroenteritis and persistent vomiting]. ( Wichers, IM, 2022) |
| "Postoperative pain was treated successfully in both groups." | 2.78 | Ondansetron does not attenuate the analgesic efficacy of nefopam. ( Chen, J; Chen, Y; Li, MG; Lu, KZ; Shen, H; Tian, GP, 2013) |
| "Ondansetron exposure was equivalent in regimens B and C." | 2.74 | Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. ( Adams, L; Blum, R; Johnson, B; Lates, C; Lebowitz, P; Lu, E; Zhang, K, 2009) |
| "Pioglitazone was further assessed as a mechanism-based inhibitor." | 1.40 | Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro. ( Nagar, S; Parkman, HP; Youssef, AS, 2014) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 2 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Wichers, IM | 1 |
| Mansour, M | 2 |
| Nasr, M | 2 |
| Ahmed-Farid, OAH | 2 |
| Ahmed, RF | 2 |
| Osman, AAM | 1 |
| Elhassan, MMA | 1 |
| AbdElrahim, BHA | 1 |
| Ahmed, FHA | 1 |
| Yousif, JBH | 1 |
| Ahmed, MAM | 1 |
| Abdelhafeez, RHA | 1 |
| Ahmed, UMY | 1 |
| Darpo, B | 1 |
| Benson, C | 1 |
| Brown, R | 1 |
| Dota, C | 1 |
| Ferber, G | 1 |
| Ferry, J | 1 |
| Jarugula, V | 1 |
| Keirns, J | 1 |
| Ortemann-Renon, C | 1 |
| Pham, T | 1 |
| Riley, S | 1 |
| Sarapa, N | 1 |
| Ticktin, M | 1 |
| Zareba, W | 1 |
| Couderc, JP | 1 |
| Lu, KZ | 1 |
| Shen, H | 1 |
| Li, MG | 1 |
| Tian, GP | 1 |
| Chen, J | 1 |
| Youssef, AS | 1 |
| Parkman, HP | 1 |
| Nagar, S | 1 |
| Kovács, G | 1 |
| Wachtel, AE | 1 |
| Basharova, EV | 1 |
| Spinelli, T | 1 |
| Nicolas, P | 1 |
| Kabickova, E | 1 |
| Nakagaki, M | 1 |
| Barras, M | 1 |
| Curley, C | 1 |
| Butler, JP | 1 |
| Kennedy, GA | 1 |
| Bell, GC | 1 |
| Caudle, KE | 1 |
| Whirl-Carrillo, M | 1 |
| Gordon, RJ | 1 |
| Hikino, K | 1 |
| Prows, CA | 1 |
| Gaedigk, A | 1 |
| Agundez, J | 1 |
| Sadhasivam, S | 1 |
| Klein, TE | 1 |
| Schwab, M | 1 |
| Gore, L | 1 |
| Chawla, S | 1 |
| Petrilli, A | 1 |
| Hemenway, M | 1 |
| Schissel, D | 1 |
| Chua, V | 1 |
| Carides, AD | 1 |
| Taylor, A | 1 |
| Devandry, S | 1 |
| Valentine, J | 1 |
| Evans, JK | 1 |
| Oxenius, B | 1 |
| Johnson, B | 1 |
| Adams, L | 1 |
| Lu, E | 1 |
| Zhang, K | 1 |
| Lebowitz, P | 1 |
| Lates, C | 1 |
| Blum, R | 1 |
| Nathan, PC | 1 |
| Tomlinson, G | 1 |
| Dupuis, LL | 1 |
| Greenberg, ML | 1 |
| Ota, S | 1 |
| Bartels, U | 1 |
| Feldman, BM | 1 |
| Dłuzniewska, A | 1 |
| Balwierz, W | 1 |
| Armata, J | 1 |
| Eliasińska, A | 1 |
| Thavaraj, V | 1 |
| Arya, LS | 1 |
| McCune, JS | 1 |
| Oertel, MD | 1 |
| Pfeifer, D | 1 |
| Houston, SA | 1 |
| Bingham, A | 1 |
| Sawyer, WT | 1 |
| Lindley, CM | 1 |
| Culy, CR | 1 |
| Bhana, N | 1 |
| Plosker, GL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical ECG Study to Evaluate Electrophysiological Effects of Potential QT Prolonging Drugs With Novel ECG Biomarkers With Exposure-Response Analysis[NCT05716854] | Phase 1 | 44 participants (Actual) | Interventional | 2023-03-21 | Completed | ||
| A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC o[NCT01442376] | Phase 3 | 502 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated W[NCT00080444] | Phase 3 | 50 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients[NCT01757210] | 20 participants (Actual) | Observational | 2012-09-30 | Completed | |||
| An Open-Label, Phase I Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Intravenous and Oral Doses of Dexamethasone and Intravenous and Oral Doses of Ondansetron When Administered in Healthy Adult Subjects[NCT00437229] | Phase 1 | 37 participants (Actual) | Interventional | 2007-02-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Complete Response (CR) was defined as no vomiting, no retching, and no use of antiemetic rescue medication from >24 to 120 hours (delayed phase) after T0 (start of administration of the most emetogenic chemotherapy) during first cycle. (NCT01442376)
Timeframe: from >24 to 120 hours (delayed phase) after T0
| Intervention | percentage of patients (Number) |
|---|---|
| Palonosetron 10 mcg/kg | 28.9 |
| Palonosetron 20 mcg/kg | 38.8 |
| Ondansetron | 28.4 |
Complete Response (CR) was defined as no vomiting, no retching, and no use of antiemetic rescue medication from 0 to 24 hours (acute phase) after T0 (start of administration of the most emetogenic chemotherapy) during first cycle. Time 0 (T0) is defined as the time when the patient starts the first cycle of chemotherapy. (NCT01442376)
Timeframe: 0 to 24 hours after T0
| Intervention | percentage of patients (Number) |
|---|---|
| Palonosetron 10 mcg/kg | 54.2 |
| Palonosetron 20 mcg/kg | 59.4 |
| Ondansetron | 58.6 |
3 reviews available for ondansetron and Adverse Drug Event
| Article | Year |
|---|---|
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.
Topics: Antiemetics; Cytochrome P-450 CYP2D6; Drug-Related Side Effects and Adverse Reactions; Genetic Testi | 2017 |
Ondansetron.
Topics: Administration, Oral; Adult; Antiemetics; Child; Child, Preschool; Clinical Trials as Topic; Drug-Re | 1995 |
Ondansetron: a review of its use as an antiemetic in children.
Topics: Adolescent; Antiemetics; Child; Clinical Trials as Topic; Dexamethasone; Drug-Related Side Effects a | 2001 |
7 trials available for ondansetron and Adverse Drug Event
| Article | Year |
|---|---|
Evaluation of the Effect of 5 QT-Positive Drugs on the JTpeak Interval - An Analysis of ECGs From the IQ-CSRC Study.
Topics: Arrhythmias, Cardiac; Biomarkers; Cetirizine; Drug-Related Side Effects and Adverse Reactions; Elect | 2020 |
Ondansetron does not attenuate the analgesic efficacy of nefopam.
Topics: Adult; Aged; Analgesics; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; | 2013 |
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confidence Intervals; Dose- | 2016 |
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepine | 2017 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
Topics: Adolescent; Adult; Antiemetics; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects | 2009 |
A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.
Topics: Antiemetics; Antineoplastic Agents; Bayes Theorem; Brain Neoplasms; Child; Child, Preschool; Cisplat | 2006 |
10 other studies available for ondansetron and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
[No place for ondansetron in young children with gastroenteritis and persistent vomiting].
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Diarrhea; Double-Blind Method; Drug-Rela | 2022 |
Intranasal ondansetron microemulsion counteracting the adverse effects of cisplatin: animal study.
Topics: Animals; Antiemetics; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Ondansetron; Rats; | 2023 |
Intranasal ondansetron microemulsion counteracting the adverse effects of cisplatin: animal study.
Topics: Animals; Antiemetics; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Ondansetron; Rats; | 2023 |
Intranasal ondansetron microemulsion counteracting the adverse effects of cisplatin: animal study.
Topics: Animals; Antiemetics; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Ondansetron; Rats; | 2023 |
Intranasal ondansetron microemulsion counteracting the adverse effects of cisplatin: animal study.
Topics: Animals; Antiemetics; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Ondansetron; Rats; | 2023 |
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therap | 2018 |
Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro.
Topics: Antiemetics; Chromatography, Liquid; Cytochrome P-450 CYP3A; Domperidone; Drug Interactions; Drug-Re | 2014 |
[Evaluation of +ondansetron (Zolfiran) in prevention of vomiting in children treated with cytostatics].
Topics: Adolescent; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Female; Humans | 1995 |
Reports from the University Hospital Consortium (UHC) Technology Advancement Center.
Topics: Academic Medical Centers; Drug-Related Side Effects and Adverse Reactions; Multicenter Studies as To | 1995 |
Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Child; Constipation; Diarrhea; Drug Utilizatio | 2001 |